News Medical

Groundbreaking G6PD diagnostic test prequalified by WHO to ensure safe malaria treatment

On 18 December 2024, the World Health Organization (WHO) prequalified the first diagnostic test for glucose-6-phosphate dehydrogenase (G6PD) deficiency which can help to safely deliver WHO-recommended ...
Business Wire

MedTest Dx Manufactures the Only FDA Approved Quantitative Test for G6PD, Critical when Considering COVID-19 Treatment with Chloroquine and Hydroxychloroquine

-Accurate, Plug and Play Test Measures G6PD Activity in Whole Blood, Detecting Both Presence and Severity of G6PD Deficiency, Providing Key Insight to Inform Drug Therapy Options CANTON, ...
Pharmabiz

US FDA grants 510(k) clearance for Baebies G6PD test on FINDER platform

Baebies has received US Food and Drug Administration (FDA) 510(k) clearance for its rapid, point-of-care test for glucose-6-phosphate dehydrogenase (G6PD) deficiency. The test is run on the FINDER ...
Nature

Glucose-6-phosphate dehydrogenase (G6PD) mutations in Cambodia: G6PD Viangchan (871G>A) is the most common variant in the Cambodian population

We conducted a survey of malaria diagnoses and glucose-6-phosphate dehydrogenase (G6PD) testing in remote areas of Cambodia. Blood specimens from 670 people were collected by the finger-prick method.
Nature

Should we screen newborns for glucose-6-phosphate dehydrogenase deficiency in the United States?

Glucose-6-phosphate dehydrogenase (G6PD) deficiency, a common X-linked enzymopathy can lead to severe hyperbilirubinemia, acute bilirubin encephalopathy and kernicterus in the United States. Neonatal ...
WGNO

Baebies Receives FDA 510(k) Clearance for G6PD Test on FINDER Platform

DURHAM, N.C., Nov. 9, 2022 /PRNewswire/ -- Baebies has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its rapid, point-of-care test for glucose-6-phosphate dehydrogenase (G6PD) ...